Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence
Authors:
- Elaine A DunlopElaine A Dunlop
- Kayleigh M DoddKDKayleigh M Dodd
- Stephen C LandStephen C Land
- Peter A DaviesPDPeter A Davies
- Nicole MartinsNMNicole Martins
- Helen StuartHSHelen Stuart
- Shane McKeeSMShane McKee
- Chris KingswoodCKChris Kingswood
- Anand SaggarASAnand Saggar
- Isabel CorderioICIsabel Corderio
- Ana Maria Duarte MedeiraAMAna Maria Duarte Medeira
- Helen KingstonHKHelen Kingston
- 16 March 2011
- journal article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 19 (7) , 789-795
Abstract
Tuberous sclerosis complex (TSC) is a genetic condition characterized by the growth of benign tumours in multiple organs, including the brain and kidneys, alongside intellectual disability and seizures. Identification of a causative mutation in TSC1 or TSC2 is important for accurate genetic counselling in affected families, but it is not always clear from genetic data whether a sequence variant is pathogenic or not. In vitro functional analysis could provide support for determining whether an unclassified TSC1 or TSC2 variant is disease-causing. We have performed a detailed functional analysis of four patient-derived TSC2 mutations, E92V, R505Q, H597R and L1624P. One mutant, E92V, functioned similarly to wild-type TSC2, whereas H597R and L1624P had abnormal function in all assays, consistent with available clinical and segregation information. One TSC2 mutation, R505Q, was identified in a patient with intellectual disability, seizures and autistic spectrum disorder but who did not fulfil the diagnostic criteria for TSC. The R505Q mutation was also found in two relatives, one with mild learning difficulties and one without apparent phenotypic abnormality. R505Q TSC2 exhibited partially disrupted function in our assays. These data highlight the difficulties of assessing pathogenicity of a mutation and suggest that multiple lines of evidence, both genetic and functional, are required to assess the pathogenicity of some mutations.Keywords
This publication has 24 references indexed in Scilit:
- Identification of a region required for TSC1 stability by functional analysis of TSC1missense mutations found in individuals with tuberous sclerosis complexBMC Medical Genetics, 2009
- Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein–protein interactions for substrate recognitionCellular Signalling, 2009
- The Human Variome ProjectScience, 2008
- A reliable cell-based assay for testing unclassified TSC2 gene variantsEuropean Journal of Human Genetics, 2008
- Missense mutations to the TSC1 gene cause tuberous sclerosis complexEuropean Journal of Human Genetics, 2008
- Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningJournal of Cell Biology, 2006
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR ActionCell, 2002
- Comprehensive Mutation Analysis of TSC1 and TSC2—and Phenotypic Correlations in 150 Families with Tuberous SclerosisThe American Journal of Human Genetics, 1999
- Identification and characterization of the tuberous sclerosis gene on chromosome 16Cell, 1993